Intervention
Palbociclib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 168 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22
RECRUITINGA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerNCT07347600 · 2026-01-21
RECRUITINGA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22
RECRUITINGA Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · 2025-08-01
RECRUITINGA Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNCT06856200 · 2025-02-28
RECRUITINGThe CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyNCT06377852 · 2024-10-29
RECRUITINGSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01
RECRUITINGA First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsNCT06188520 · 2023-12-05
RECRUITINGStudy of AVZO-021 in Patients With Advanced Solid TumorsNCT05867251 · 2023-08-30
RECRUITINGPredicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01
RECRUITINGFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · 2023-04-17
RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07
RECRUITINGA Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerNCT05683418 · 2023-02-15
RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerNCT04802759 · 2021-06-22
RECRUITINGAvelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerNCT04841148 · 2021-06-01
RECRUITINGStudy of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446 · 2020-11-16
RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerNCT03424005 · 2018-03-30
RECRUITINGPalbociclib and Pembrolizumab In Central Nervous System MetastasesNCT02896335 · 2017-02-02
RECRUITINGA Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesNCT07748208 · 2026-10-30
NOT_YET_RECRUITINGA Phase 1/2a Study of K-1728 in Advanced Solid TumorsNCT07861932 · 2026-10-01
NOT_YET_RECRUITINGT-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdNCT07683754 · 2026-09-04
NOT_YET_RECRUITINGPalbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.NCT06338644 · 2024-07-01
UNKNOWNA Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerNCT06495164 · 2024-06-24
ACTIVE_NOT_RECRUITINGOPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNCT05949424 · 2024-05-01
UNKNOWNBinimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerNCT04870034 · 2024-01-15
WITHDRAWNA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11
ACTIVE_NOT_RECRUITINGPalbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer PatientsNCT06076772 · 2023-11-01
NOT_YET_RECRUITINGA Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other OrgansNCT06003114 · 2023-10-06
COMPLETEDStudy to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.NCT06086340 · 2023-09-29
COMPLETEDVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerNCT05909397 · 2023-08-09
ACTIVE_NOT_RECRUITINGFirst-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsNCT05759949 · 2023-03-29
COMPLETEDSMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWNOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerNCT05563220 · 2023-01-24
ACTIVE_NOT_RECRUITINGPhase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerNCT05384119 · 2023-01-09
TERMINATEDGedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · 2022-12-08
ACTIVE_NOT_RECRUITINGA Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCNCT05766410 · 2022-09-16
UNKNOWNStudy for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesNCT05226871 · 2022-07-07
ACTIVE_NOT_RECRUITINGStudy of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922 · 2022-07-05
ACTIVE_NOT_RECRUITINGPhase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast CancerNCT05293964 · 2022-05-18
ACTIVE_NOT_RECRUITINGPhase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent ThromboinflammationNCT05371275 · 2022-04-21
WITHDRAWNStudy to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in JapanNCT05399329 · 2022-04-20
COMPLETEDCyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" StudyNCT05067530 · 2022-01-01
NOT_YET_RECRUITINGStudy Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up PeriodNCT05135104 · 2021-12-15
UNKNOWNA Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsNCT05266105 · 2021-12-10
ACTIVE_NOT_RECRUITINGONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerNCT06570031 · 2021-11-09
COMPLETEDNeoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerNCT05076695 · 2021-10-15
UNKNOWNA Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast CancerNCT04872608 · 2021-09-09
WITHDRAWNA Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerNCT04946864 · 2021-08-13
SUSPENDEDER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)NCT04669587 · 2021-07-26
UNKNOWNPhase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934 · 2021-06-30
ACTIVE_NOT_RECRUITINGCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)NCT04862663 · 2021-05-10
ACTIVE_NOT_RECRUITINGTumor Response Time of Palbociclib in Combination With AI in Real-world Chinese PatientsNCT04858997 · 2021-04-22
UNKNOWNStudy of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast CancerNCT04856371 · 2021-04-01
UNKNOWNAbexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520 · 2021-03-31
WITHDRAWNDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)NCT04567420 · 2021-02-09
ACTIVE_NOT_RECRUITINGA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseNCT04711252 · 2021-01-28
ACTIVE_NOT_RECRUITINGAnalysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.NCT04852081 · 2021-01-01
UNKNOWNHOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerNCT03685331 · 2020-10-15
COMPLETEDAmcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast CancerNCT04478266 · 2020-10-14
TERMINATEDA Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)NCT04546009 · 2020-10-09
ACTIVE_NOT_RECRUITINGCommon conditions
Breast Cancer56Metastatic Breast Cancer37Advanced Breast Cancer10Breast Neoplasms9Anatomic Stage IV Breast Cancer AJCC v87Human Epidermal Growth Factor 2 Negative Carcinoma of Breast7HER2/Neu Negative6Metastatic Breast Carcinoma6Advanced Malignant Solid Neoplasm5Breast Carcinoma5HER2-positive Breast Cancer5Locally Advanced Breast Cancer5Prognostic Stage IV Breast Cancer AJCC v85Anatomic Stage III Breast Cancer AJCC v84Breast Cancer Stage IV4Hormone Receptor Positive Tumor4Recurrent Ovarian Carcinoma4Solid Tumors4Stage IV Breast Cancer4Breast Cancer Female3Breast Diseases3Breast Neoplasm3Estrogen Receptor Positive3Estrogen Receptor-positive Breast Cancer3Hormone Receptor Positive Malignant Neoplasm of Breast3
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
breast cancer56breast carcinoma5HER2 positive breast carcinoma4hormone receptor-positive breast cancer4breast disorder3breast neoplasm3non-small cell lung carcinoma3ovarian carcinoma3cancer2colorectal carcinoma2endometrial carcinoma2estrogen-receptor positive breast cancer2head and neck cancer2hepatocellular carcinoma2lung cancer2prostate cancer2thyroid gland carcinoma2adenocarcinoma1anemia1atypical chronic myeloid leukemia, BCR-ABL1 negative1
Leading sponsors
Pfizer
15
Hoffmann-La Roche
9
Dana-Farber Cancer Institute
8
AstraZeneca
6
National Cancer Institute (NCI)
5
Emory University
3
Fudan University
3
Genentech, Inc.
3
MedSIR
3
Abramson Cancer Center at Penn Medicine
2
Bristol-Myers Squibb
2
Celcuity Inc
2
Eli Lilly and Company
2
ETOP IBCSG Partners Foundation
2
Georgetown University
2
Trial status mix
COMPLETED64
ACTIVE_NOT_RECRUITING35
UNKNOWN20
RECRUITING18
TERMINATED16
WITHDRAWN7
NOT_YET_RECRUITING5
SUSPENDED2
NO_LONGER_AVAILABLE1
Phase mix
PHASE283
PHASE154
PHASE322
EARLY_PHASE14
NA3
PHASE43
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.